Galectin-3 Enhances Vascular Endothelial Growth Factor-A Receptor 2 Activity in the Presence of Vascular Endothelial Growth Factor.
angiogenesis
endothelium
glycocalyx
migration
ranibizumab
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
07
2021
accepted:
30
08
2021
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
8
10
2021
Statut:
epublish
Résumé
Galectin-3 (Gal3) is a carbohydrate-binding protein reported to promote angiogenesis by influencing vascular endothelial growth factor-A receptor 2 (VEGFR2) signal transduction. Here we evaluated whether the ability of Gal3 to function as an angiogenic factor involved vascular endothelial growth factor (VEGF). To address this possibility we used human retinal microvascular endothelial cells (HRECs) to determine whether exogenous Gal3 requires VEGF to activate VEGFR2 signaling and if Gal3 is required for VEGF to activate VEGFR2. VEGFR2 phosphorylation and HREC migration assays, following either VEGF neutralization with ranibizumab or Gal3 silencing, revealed that VEGF endogenously produced by the HRECs was essential for the effect of exogenous Gal3 on VEGFR2 activation and cell migration, and that VEGF-induced VEGFR2 activation was not dependent on Gal3 in HRECs. Gal3 depletion led to no reduction in VEGF-induced cell function. Since Gal3 has been suggested to be a potential therapeutic target for VEGFR2-mediated angiogenesis, it is crucial to define the possible Gal3-mediated VEGFR2 signal transduction mechanism to aid the development of efficacious therapeutic strategies.
Identifiants
pubmed: 34616740
doi: 10.3389/fcell.2021.734346
pmc: PMC8488270
doi:
Types de publication
Journal Article
Langues
eng
Pagination
734346Subventions
Organisme : NEI NIH HHS
ID : R01 EY026539
Pays : United States
Informations de copyright
Copyright © 2021 Cano, Hu, AbuSamra, Saint-Geniez, Ng, Argüeso and D’Amore.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunol Rev. 2009 Jul;230(1):160-71
pubmed: 19594635
J Biol Chem. 2001 Mar 9;276(10):7614-20
pubmed: 11108718
Clin Cancer Res. 2013 Apr 1;19(7):1693-704
pubmed: 23401226
PLoS One. 2014 Nov 04;9(11):e111836
pubmed: 25369125
Biochem J. 2011 Jul 15;437(2):169-83
pubmed: 21711246
Nat Rev Mol Cell Biol. 2006 May;7(5):359-71
pubmed: 16633338
Laryngoscope. 2008 Sep;118(9):1583-90
pubmed: 18677282
J Exp Med. 2010 Aug 30;207(9):1981-93
pubmed: 20713592
Exp Cell Res. 2007 May 1;313(8):1561-74
pubmed: 17382929
J Biol Chem. 2006 Sep 15;281(37):27178-89
pubmed: 16829530
Int J Immunopathol Pharmacol. 2013 Apr-Jun;26(2):327-35
pubmed: 23755748
Prostate. 2000 Jul 1;44(2):118-23
pubmed: 10881021
PLoS One. 2013 Jun 17;8(6):e67029
pubmed: 23799140
Am J Pathol. 2000 Sep;157(3):815-23
pubmed: 10980121
Ophthalmol Retina. 2020 Dec;4(12):1138-1145
pubmed: 31937473
Cell Commun Signal. 2019 Jun 17;17(1):65
pubmed: 31208421
J Pathol. 1996 May;179(1):43-8
pubmed: 8691344
J Biol Chem. 2011 Aug 26;286(34):29913-21
pubmed: 21715322
Proteins. 2017 Aug;85(8):1529-1549
pubmed: 28486782
Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25
pubmed: 27461391
Br J Ophthalmol. 2013 Nov;97(11):1443-6
pubmed: 23966368
Sci Rep. 2017 Dec 7;7(1):17138
pubmed: 29215001
Nat Med. 1995 Jan;1(1):27-31
pubmed: 7584949
FASEB J. 2019 Aug;33(8):9362-9373
pubmed: 31141406
Int J Mol Sci. 2018 Apr 23;19(4):
pubmed: 29690653
Am J Pathol. 2000 Mar;156(3):899-909
pubmed: 10702407
PLoS One. 2013 Aug 19;8(8):e72304
pubmed: 23977277
Clin Ophthalmol. 2013;7:1987-93
pubmed: 24143065
Glycobiology. 2014 Oct;24(10):886-91
pubmed: 25138305